Publications — Stanley Lee Lab

See the full publication list on MyNCBI and Google Scholar.

2024

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts

Zhiyan SL, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi VM, Takashima K, Zong D, Corral V, Nguyen E, Yoo J, Chiraphapphaiboon W, Leibson C, McMahon MC, Rai S, Swisher EM, Sachs Z, Chatla S, Stirewalt DL, Deeg JH, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC#, Nguyen HD#

Cancer Research (2024) 84 (4): 577–597, PMID: 37967363 #Co-corresponding author

2023

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.

Totiger TM, Chaudhry S, Musi E, Afaghani J, Montoya S, Owusu-Ansah F, Lee SC, Schwartz G, Klimek V, Taylor J.

Journal of Cellular and Molecular Biomedicine. 2023 Feb; 27 (4):587-590. PMID: 36722323.

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.

Pogosova-Agadjanyan EL, Hua X, Othus M, Appelbaum FR, Chauncey TR, Erba HP, Fitzgibbon MP, Jenkins IC, Fang M, Lee SC, Moseley A, Naru J, Radich JP, Smith JL, Willborg BE, Willman CL, Wu F, Meshinchi S, Stirewalt DL.

Biomark Res. 2023 Mar 16;11(1):31. PMID: 36927800.

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.

Termini CM, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Erba HP, Fang M, Lee SC, Naru J, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Wu F, Meshinchi S, Stirewalt DL.

Hematologica. 2023 Apr 6; DOI:10.3324/haematol.2023.282733. PMID: 37021537.

BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state

Xiao M, Kondo S, Nomura M, Kato S, Nishimura K, Zang W, Zhang Y, Akashi T, Viny A, Shigehiro T, Ikawa T, Yamazaki H, Fukumoto M, Tanaka A, Hayashi Y, Koike Y, Aoyama Y, Ito H, Nishikawa H, Kitamura T, Kanai A, Yokoyama A, Fujiwara T, Goyama S, Noguchi H, Lee SC, Toyoda A, Hinohara K, Abdel-Wahab O, Inoue D.

Nature Communications. 2023 Dec 15;14(1):8372. PMID: 38102116.

Therapeutic Targeting of RNA Splicing in Cancer

Bonner E, Lee SC*. Co-Corresponding Author

Genes. 2023 Jun 29;14(7):1378. PMID: 37510283.

2022

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.

Tanaka A, Nakano TA, Nomura M, Yamazaki H, Bewersforf JP, Mulet-Lazaro R, Hogg S, Liu B, Penson A, Yokoyama A, Zang W, Havermans M, Koizumi M, Hayashi Y, Cho H, Kanai A, Lee SC, Xiao M, Koike Y, Zhang Y, Fukumoto M, Aoyama Y, Konuma T, Kunimoto H, Inaba T, Nakajima H, Honda H, Kawamoto H, Delwel R, Abdel-Wahab O, Inoue D.

Blood. 2022 Aug 25; 140(8):875-888. PMID: 35709354.

2021

DEAD-Box RNA Helicases and Genomic Instability

Cargill M, Venkataraman R, Lee SC*. Co-corresponding Author

Genes. 2021 Sep 23 ;12(10):1471. PMID: 34680866.

2020

Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization.

Liu Z, Yoshimi A, Wang J, Cho H, Lee SC, Ki M, Bitner L, Chu T, Shah H, Liu B, Mato AR, Ruvolo P, Fabbri G, Pasqualucci L, Abdel-Wahab O, Rabadan R.

Cancer Discovery. 2020 Jun;10(6):806-821. PMID: 32188705.

DNA methylation disruption reshapes the hematopoietic differentiation landscape.

Izzo F*, Lee SC*, Poran A, Chaligne R, Deochand SD, Viny A, Nam A, Kim KT, Hothen-Hill S, Schulman R, Ki M, Lhoumaud P, Skok J, Levine RL, Abdel-Wahab O, Kenigsberg E, Landau DA. *Equal Contribution

Nature Genetics. 2020 Apr;52(4):378-387. PMID: 32203468.

Menin inhibitor MI-3454 induces remission in MLL-rearranged and NPM1-mutated models of leukemia.

Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber TA, Choi SM, Sun D, Ren P, Li LS, Liu Y, Burrows FJ, Maillard I, Cierpicki T, Grembecka J.

Journal of Clinical Investigation. 2020 Feb 3;130(2):981-997. PMID: 31855575.

2019

Spliceosomal disruption of the non-canonical BAF complex in cancer.

Inoue D, Chew G, Liu B, Michel BC, Pangallo J, D'Avino AR, Hitchman T, North K, Lee SC, Bitner L, Block A, Moore AR, Yoshimi A, Escobar-Hoyos L, Cho H, Penson A, Taylor J, Lu SX, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK.

Nature. 2019 Oct;574(7778):432-436. PMID: 31597964.

Coordinated alterations in RNA splicing and epigenetic regulation drive leukemogenesis.

Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Intlekofer AM, Wang B, Lee SC, Micol J-B, Zhang XJ, de Botton S, Penard-Lacronique V, Stein E, Cho H, Miles RE, Inoue D, Albrecht TR, Somervaille TCP, Thompson CB, Levine RL, Dvinge H, Bradley RK, Wagner EJ, Krainer AR, Abdel- Wahab O.

Nature. 2019 Oct;574(7777):273-277. PMID: 31578525.

Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.

Taylor J, Lee SC*. Corresponding author.

Genes Chromosomes Cancer. 2019 Dec;58(12):889-902. PMID: 31334570.

Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation.

Fong JY, Pignata L, Goy P-A, Kawabata KC, Lee SC, Koh CM, Musiani D, Massignani E, Kotini A, Penson A, Wun CM, Shen Y, Schwarz M, Low DHP, Rialdi A, Ki M, Wollmann H, Mzoughi S, Gay F, Thompson C, Hart T, Barbash O, Muciani GM, Szewczyk MM, Wouters BJ, Delwel R, Papapetrou EP, Barsyte-Lovejoy D, Arrowsmith CH, Minden MD, Jin J, Melnick A, Bonaldi T, Abdel-Wahab O, Guccione E.

Cancer Cell. 2019 Aug 12:36(2):194-209. PMID: 31408619.

Altered nuclear export signal recognition as a driver of oncogenesis.

Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila El, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O.

Cancer Discovery. 2019 Oct;9(10):1452-1467. PMID: 31285298.

Targeting an RNA-binding protein network in acute myeloid leukemia.

Wang E, Lu SX, Pastore A, Chen X, Imig J, Lee SC, Ghebrechristos Y, Yoshimi A, Bitner LE, Ki M, Kloetgen A, Lin K, Tibes R, Krainer AR, Uehara T, Owa T, Abdel-Wahab O, Aifantis I.

Cancer Cell. 2019 Mar 18;35(3):369-384. PMID: 30799057.

2018

Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations.

Lee SC*, North K*, Kim E*, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O. *Equal contribution.

Cancer Cell. 2018 Aug 13;34(2):225-241. PMID: 30107174.

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal A, Caleb B, Csibi A, Eckley S, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nature Medicine. 2018 May;24(4):497-504. PMID: 29457796.

2017

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Leston C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27; 130(4);397-407. PubMed PMID: 28576879.

Modeling CBL activating mutations in vivo .

Lee SC, Abdel-Wahab O.

Blood. 2017 Apr 13;129(15):2046-2048. PMID: 28408421.

A non-canonical function of Ezh2 preserves immune homeostasis.

Vasanthakumar A, Xu D, Lun AT, Kueh AJ, van Gisbergen KP, Iannarella N, Li X, Yu L, Wang D, Williams BR, Lee SC, Majewski IJ, Godfrey DI, Smyth GK, Alexander WS, Herold MJ, Kallies A, Nutt SL, Allan RS.

EMBO Reports. 2017 Apr;18(4):619-631. PMID: 28223321.

ASXL2 is essential for normal hematopoiesis and a haploinsufficient tumor suppressor in leukemia.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang X, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O.

Nature Communications. 2017 May 18;8:15429. PMID: 28516957.

2016

Therapeutic targeting of splicing in cancer.

Lee SC, Abdel-Wahab O.

Nature Medicine. 2016 Sep:7;22(9):976-86. PMID: 27603132.

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Lee SC*, Dvinge H*, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. *Equal contribution.

Nature Medicine. 2016 Jun;22(6):672-8. PMID: 27135740.

Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression.

Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK.

Annals of Applied Statistics. 2016 Jun;10(2):946-63. PMID: 28367255.

Diverse and targetable kinase alterations drive histiocytic neoplasms.

Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylbester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O.

Cancer Discovery. 2016 Feb;6(2):154-65. PMID: 26566875.

2015

BET inhibitor resistance merges from leukaemia stem cells.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson S-J, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA.

Nature. 2015 Sep 24;525(7570):538-42. PMID: 26367796.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oles M, Else M, Lui X, Slabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel-Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. PMID: 26065650.

Polycomb Repressive Complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.

Lee SC, Miller S, Hyland C, Kauppi M, Lebois M, DiRago L, Metcalf D, Kinkel SA, Josefsson EC, Blewitt ME, Majewski IJ, Alexander WS.

Blood. 2015 Jul 9;126(2):167-75. PMID: 26036803.

SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition.

Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, Cho H, Kim MK, Zebari AS, Aumann S, Park CY, Buonamici S, Smith PG, Deeg HJ, Lobry C, Aifantis I, Modis Y, Allain FH, Halene S, Bradley RK, Abdel-Wahab O.

Cancer Cell. 2015 May 11;27(5):617-630. PMID: 25965569.

Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2.

Kinkel SA, Galeev R, Flensburg C, Keniry A, Breslin K, Gilan O, Lee S, Chen K, Gearing LJ, Moore DL, Alexander WS, Dawson M, Majewski IJ, Oshlack A, Larsson J, Blewitt M.

Blood. 2015 Mar 19;125(12):1890-900. PMID: 25645357.